طريقة بسيطة معدلة لتحريض احتشاء عضلة القلب في الفئران

Executive Industry Relevance

Robust in vivo myocardial infarction (MI) models are essential for preclinical evaluation of cardiac therapeutics and mechanistic studies of post-MI remodeling. This streamlined coronary artery ligation protocol enables reproducible MI induction in mice, supporting translational research and early-stage therapeutic hypothesis testing. The method's accessibility and efficiency facilitate broader adoption across discovery and preclinical R&D portfolios.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of cardiac injury pathways and post-MI remodeling mechanisms.
• Supports functional validation of therapeutic targets in a disease-relevant in vivo context.
• Facilitates mechanistic de-risking for candidate interventions targeting cardiac repair.

Screening & Assay Development

• Provides a standardized platform for evaluating efficacy of gene or cell therapies post-MI.
• Delivers reproducible infarct size and contractile dysfunction for quantitative assessment.
• Enables downstream integration with imaging and histological assays for robust readouts.

Translational & Preclinical Research

• Aligns with disease-relevant endpoints such as ventricular remodeling and survival analysis.
• Supports continuity from mechanistic discovery to preclinical therapeutic validation.
• Allows for assessment of intervention timing and impact on post-MI outcomes.

Pipeline & Workflow Integration

This MI induction protocol fits at the interface of early discovery and preclinical validation, enabling hypothesis-driven studies and candidate screening in a physiologically relevant model.

• Discovery Biology: Facilitates hypothesis testing on cardiac injury and repair mechanisms.
• Screening: Provides reproducible infarct induction for comparative efficacy studies.
• Analytics: Supports quantitative measurement of infarct size, contractile function, and survival.
• Translational Research: Bridges mechanistic insights to preclinical therapeutic evaluation in vivo.
• Enterprise Reuse: Offers a scalable, accessible model for diverse cardiac research programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in target validation and mechanistic studies.
• Operational Value: Standardizes MI induction, reducing technical variability and training burden.
• Strategic Value: Accelerates go/no-go decisions for cardiac therapeutic candidates.
• Portfolio Impact: Enables risk-adjusted prioritization of interventions targeting post-MI remodeling.

Implementation Considerations

• Requires surgical proficiency and familiarity with murine cardiac anatomy.
• Needs access to basic surgical instruments and post-operative care infrastructure.
• Demands cross-team standardization for reproducibility in multi-site studies.
• Adaptable to gene or cell therapy delivery post-ligation for intervention studies.
• Mortality and technical variability must be monitored and reported for data integrity.

Biopharma FAQs